MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...
Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium ...
A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...
A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your ...
For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...
Russell has a PhD in the history of medicine, violence, and colonialism. His research has explored topics including ethics, science governance, and medical involvement in violent contexts. Russell has ...
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
Zenas BioPharma shares jumped in premarket trading after the company reported highly positive trial data for its multiple-sclerosis treatment. Shares traded over 59% higher ahead of the morning bell ...
Annual out-of-pocket costs for multiple sclerosis (MS) care in the US increased by 125% from 2002 to 2021, primarily driven by newer disease-modifying therapies (DMTs), a new study showed. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results